KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Globus Medical (GMED) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Globus Medical (GMED) over the last 15 years, with Q3 2025 value amounting to 15.56%.

  • Globus Medical's EBITDA Margin rose 64900.0% to 15.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.95%, marking a year-over-year increase of 117800.0%. This contributed to the annual value of 4.22% for FY2024, which is 45300.0% down from last year.
  • As of Q3 2025, Globus Medical's EBITDA Margin stood at 15.56%, which was up 64900.0% from 28.88% recorded in Q2 2025.
  • Globus Medical's EBITDA Margin's 5-year high stood at 28.88% during Q2 2025, with a 5-year trough of 1.31% in Q1 2024.
  • Over the past 5 years, Globus Medical's median EBITDA Margin value was 15.56% (recorded in 2025), while the average stood at 12.81%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 255600bps in 2021, then crashed by -209500bps in 2024.
  • Quarter analysis of 5 years shows Globus Medical's EBITDA Margin stood at 4.55% in 2021, then surged by 361bps to 21.01% in 2022, then plummeted by -82bps to 3.82% in 2023, then grew by 6bps to 4.05% in 2024, then soared by 284bps to 15.56% in 2025.
  • Its last three reported values are 15.56% in Q3 2025, 28.88% for Q2 2025, and 13.4% during Q1 2025.